Premium
Bidirectional Heterologous Desensitization of Opioid and Chemokine Receptors
Author(s) -
ROGERS T. J.,
STEELE A. D.,
HOWARD O. M.Z.,
OPPENHEIM J. J.
Publication year - 2000
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2000.tb05369.x
Subject(s) - damgo , chemotaxis , chemokine , opioid , chemistry , monocyte , desensitization (medicine) , agonist , enkephalin , receptor , immunology , pharmacology , biology , biochemistry
A bstract : Opioids are known to suppress a number of elements of the immune response, including antimicrobial resistance, antibody production, and delayed‐type hypersensitivity. Phagocytic cells may be particularly susceptible to opioid administration, since reduced production of the cytokines IL‐1, IL‐6 and TNF‐α, monocyte‐mediated phagocytosis, and both neutrophil and monocyte chemotaxis have all been well established. Earlier studies have shown that both μ‐ and δ‐opioid agonists induce a chemotactic response in monocytes and neutrophils. In addition, μ‐ and δ‐opioid administration inhibited the chemotactic response of these cell populations to a number of chemokines through a process of heterologous desensitization. We report here that μ‐, δ‐, and κ‐opioid agonists also induce a chemotactic response in T lymphocytes. Using the human T‐cell line Jurkat, we have confirmed previous observations that pre‐incubation with met‐enkephalin (MetEnk), an endogenous opioid agonist, prevents the subsequent chemotactic response to the chemokine RANTES. On the other hand, treatment with MetEnk does not alter the response to the chemokine SDF‐1α. Moreover, we found that pretreatment with RANTES prevented a subsequent response of monocytes to the μ‐opioid agonist DAMGO. These results suggest that activation of members of the opioid and chemokine receptor families leads to downregulation of each other's leukocyte migratory activities.